NSE: LAURUSLABS · 23 October 2026
- Laurus Labs Limited shares declined 1.94% to close at ₹1,963.60 on Thursday, moving within a day's range of ₹1,934.20 to ₹2,007.10.
- Laurus Labs invested ₹1,078,000,000 to acquire 107,800,000 equity shares at face value of ₹10 each via a rights issue in KRKA Pharma Private Limited. Following this investment, the total holding in the joint venture remains at 49%, consisting of 262,150,000 equity shares.
- Trading volume was 1.22 times the 20-day average daily volume.
Why is Laurus Labs share price falling on 23 October 2026?
Laurus Labs Limited shares declined 1.94% to close at ₹1,963.60 on Thursday, moving within a day's range of ₹1,934.20 to ₹2,007.10.
The broader market and sector backdrop remained subdued, as the benchmark Nifty fell 0.90% and the Nifty Pharma sector index retreated 1.04%. Laurus Labs underperformed both the headline index and its sectoral gauge during the session, extending a near-term cooling phase that includes a 2.72% loss over the past 5 trading days and a 3.46% pullback over the past 20 trading days.
While no single immediate catalyst was announced by the company on Thursday to directly spark the decline, recent corporate developments include an equity investment of ₹107.80 crore into its joint venture KRKA Pharma Private Limited via a rights issue, as well as an assigned ESG score of 82.6 (CareEdge-ESG 1+) announced earlier in October. These longer-term strategic updates provide operational context but do not explicitly explain today's downward price action.
17.38 lakh shares traded by 23 October 2026 · 03:00 PM IST. This compares with a 20-day average daily volume of 14.27 lakh shares (1.22 times). The five-day average daily volume was 12.83 lakh shares. Separately, the NSE report for 22 October 2026 showed 6.32 lakh shares delivered, representing 41.08% of that day’s traded volume. The same report recorded 59,372 trades.
The stock declined alongside broad sectoral weakness in pharmaceutical equities and broader market indices, exhibiting higher-than-average volume during the pullback without any specific negative corporate catalysts.
Latest Company Developments
Laurus Labs invested ₹1,078,000,000 to acquire 107,800,000 equity shares at face value of ₹10 each via a rights issue in KRKA Pharma Private Limited. Following this investment, the total holding in the joint venture remains at 49%, consisting of 262,150,000 equity shares.
Demonstrates ongoing capital commitment toward expanding joint venture operations and manufacturing capabilities.
CARE ESG Ratings Limited assigned an ESG rating score of 82.6 with a rating symbol of CareEdge-ESG 1+ to Laurus Labs Limited. The rating denotes a leadership position in managing environmental, social, and governance risks through disclosures, policies, and performance.
Highlights institutional recognition of the company's sustainability standards and governance practices.
The company invested ₹12,09,60,500 to acquire 1,20,96,050 equity shares at face value of ₹10 each via a rights issue in its associate company Kurnool Renewables Private Limited. This maintains its 26% shareholding with a total holding of 2,11,68,000 equity shares.
Reflects continued strategic investments in renewable energy infrastructure to support long-term sustainability goals.
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 8.26% on 30 September 2026. This compares with 10.15% on 30 June 2026, a change of -1.89 percentage points.
The filing reported 38 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming financial results and interim dividend consideration scheduled for October 29, 2026
- Execution progress on growth capital expenditures across API, formulations, peptides, and fermentation projects
- Delivery volume trends relative to the 20-day average volume of 1,737,866 shares
- Performance relative to the Nifty Pharma benchmark index
Other Dated Coverage
- Laurus Labs in Focus After Receiving CareEdge-ESG 1+ Leadership Rating | 16 October 2026 — 16 October 2026
- Laurus Labs in Focus Today After Receiving CareEdge-ESG 1+ Rating | 15 October 2026 — 15 October 2026
- Laurus Labs in Focus After ₹12.10 Crore Investment in Kurnool Renewables | 8 October 2026 — 8 October 2026
More Laurus Labs news and dated analysis →
Frequently Asked Questions
What is the latest Laurus Labs company news?
Laurus Labs invested ₹1,078,000,000 to acquire 107,800,000 equity shares at face value of ₹10 each via a rights issue in KRKA Pharma Private Limited. Following this investment, the total holding in the joint venture remains at 49%, consisting of 262,150,000 equity shares.
How strong was Laurus Labs’s trading volume?
17.38 lakh shares traded, 1.22 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:00 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.